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ly-produced JE vaccine) has been introduced into 
the routine childhood immunization programme 
in selected high-risk districts since 1997. In the first 
year that JE vaccine was provided through the EPI 
in a district, all children aged 1-5 year(s) were tar-
geted for immunization with the primary series. In 
the following and subsequent years, the children 
immunized in the previous year received a booster 
dose, and only those children aged one year received 
the primary dose series. All three doses were paedi-
atric doses (0.5 mL/dose) and were given in winter 
campaigns. However, the international standard 
for the inactivated, mouse brain-derived JE vaccine 
is to administer paediatric doses (0.5 mL/dose) to 
children aged <3 years, adult doses (1.0 mL/dose) 
to children of ≥3 years, and a total of 4-5 doses are 
given as full schedule during childhood (7).
Since introduction of JE vaccine into the routine 
childhood immunization programme in selected 
high-risk districts in HaTay province in 1997-2000, 
JE incidence rate dropped from >20 per 100,000 in 
1996 to around 5 per 100,000 in 1999, with the 
majority of cases still occurring among children 
INTRODUCTION
Japanese encephalitis (JE), a mosquitoborne viral 
disease, is highly endemic in Asia (1,2). Most JE in-
fections are asymptomatic, and only 1-3 per 1,000 
infected show clinical symptoms, such as fever, 
headache, neck stiffness, stupor, coma, convulsion, 
and, occasionally paralysis (3). Children aged <15 
years are at the highest risk (2,4). Approximately 
10-30% of JE cases are fatal, and 30-50% of the sur-
vivors suffer from long-term neurological sequelae 
(5,6). JE immunization is effecacious and cost- 
effective and has led to rapid and drastic reduction 
of JE risk in JE-endemic countries (7). 
In Viet Nam, JE remains a major cause of death 
and disability of children (8). A locally-produced, 
inactivated mouse brain-derived JE vaccine (local-
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ABSTRACT
In Viet Nam, an inactivated, mouse brain-derived vaccine for Japanese encephalitis (JE) has been given 
exclusively to ≤5 years old children in 3 paediatric doses since 1997. However, JE incidence remained 
high, especially among children aged 5-9 years. We conducted a model JE immunization programme to 
assess the feasibility and impact of JE vaccine administered to 1-9 year(s) children in 3 standard-dose regi-
men: paediatric doses for children aged <3 years and adult doses for those aged ≥3 years. Of the targeted 
children, 96.2% were immunized with ≥2 doses of the vaccine. Compared to the national immunization 
programme, JE incidence rate declined sharply in districts with the model programme (11.32 to 0.87 per 
100,000 in pre- versus post-vaccination period). The rate of reduction was most significant in the 5-9 years 
age-group. We recommend a policy change to include 5-9 years old children in the catch-up immuniza-
tion campaign and administer a 4th dose to those aged 5-9 years, who had received 3 doses of the vaccine 
during the first 2-3 years of life.
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aged <15 years. However, no further decline was 
noted during 1999-2004. To identify whether the 
continuous risk of JE after implementation of JE 
vaccination was associated with dose-schedule of 
JE vaccination and/or age group targeted for JE 
immunization, a model programme to immunize 
children at 1-9 year(s) of age with standard doses 
of JE vaccine was established. JE risk was compared 
among the 5 districts covered with the model pro-
gramme and the other 9 districts covered with the 
national programme or no JE immunization pro-
gramme.
The inactivated, mouse brain-derived vaccine pro-
duced by Green Cross, Korea (Green Cross JE Vac-
cine) was given in three standard doses: paediat-
ric doses (0.5 mL/dose) for children aged <3 years 
and adult doses (1.0 mL/dose) for those aged 3-9 
years. The first two doses were given to children at 
a 2-week interval; the third dose was administered 
a year later. 
MATERIALS AND METHODS
Study area
HaTay, a suburb of Hanoi, was selected for the model 
programme. There are 14 districts in HaTay. Each is 
composed of 15-20 communes, with a total rural 
population of 2.4 million. A majority of farmers made 
a living from rice cultivation and pig rearing. Acces-
sible and affordable healthcare network consisted of 
commune health centres, district hospital, and pro-
vincial or national hospitals. Both EPI vaccines and 
‘free-market’ vaccines were delivered through and 
documented at commune health centres.
The model programme was implemented in 5 of 
the 14 districts for demonstration in 2004 (Group 
A) (Figure 1). Of the other 9 districts, 6 had intro-
duced the locally-produced JE vaccine into the rou-
tine childhood immunization in 1997-2000 (Group 
B) (Figure 1); the remaining 3 districts had no JE 
vaccination programme (Group C). ‘Free-market’ 
JE vaccine had been available in all 14 districts at 
US$ 1-2 per dose since 1995. 
Household survey of EPI logbooks in the 5 
demonstration districts
A ‘door-to-door’ household survey was conducted 
in the Group A districts to record all children born 
after November 1994 as well as to ascertain their 
JE vaccination history by checking the pre-existing 
immunization log books at the community health 
centres and/or immunization card at homes. 
Those who had no documented previous JE vac-
cination were identified as eligible for JE immu-
Figure 1. Map of HaTay province, Viet Nam
5 districts “model programme”
6 districts “local programme”
3 districts with programme at user’s fee
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nization. Children who had an incomplete series 
were invited to receive their remaining doses but 
this group was not included in the final analysis 
of data. Age and names of children, immunized 
and not immunized, their parents’ names and ad-
dresses were logged on special forms and entered 
onto a computer database. Numbers of children by 
age from other 9 districts were obtained from EPI 
department of the Center for Disease Control and 
Prevention in HaTay.
Training and campaign publicity
Training courses on household survey and vac-
cination campaign were organized for staff mem-
bers of commune health centres. Meetings, radio 
broadcasting, and posters for campaign publicity 
were initiated 1-2 week(s) prior to each round of 
JE immunization. Written informed consent was 
obtained from parents before the first round of the 
vaccination campaign. 
Mass JE immunization campaign
Two hundred thirty-seven centres were prepared for 
the vaccination campaigns in November 2004. The 
third round of the campaign for a booster dose was 
launched in November 2005. Each round of cam-
paign lasted for 2-3 days. Children who missed one 
of the 2 doses in 2004 received 2 doses in 2005. 
Hospital-based surveillance for JE
Two Provincial Hospitals in HaTay and the Nation-
al Pediatric Hospital in Hanoi, which were most 
likely to encounter acute encephalitis patients from 
HaTay, were used as referral hospitals for JE surveil-
lance from January 2004. Paediatricians from all 14 
district hospitals were trained to recognize and to re-
fer encephalitis patients to one of the 3 surveillance 
hospitals. Residents of HaTay, aged ≤15 years, with 
a clinical diagnosis of acute encephalitis syndrome 
(AES), were enrolled as suspected JE cases. Cerebro-
spinal fluid (CSF) was collected at admission in hos-
pital. Presence of IgM antibody to JEV (anti-JEV) in 
cerebrospinal fluid (CSF) was defined as JE (9,10). 
Initial testing of specimens was performed at the 
National Pediatric Hospital Laboratory and Labo-
ratory of HaTay Center for Preventive Medicine; 
confirmatory testing of all specimens was done at 
the Virology Laboratory of Armed Forces Research 
Institute of Medical Sciences (AFRIMS), Bangkok, 
Thailand. A monthly contact with paediatric infec-
tious diseases departments and emergency depart-
ments at the 3 surveillance hospitals was made to 
check the number of patients with acute encepha-
litis and those diagnosed to have JE. 
Vaccination coverage
Children who received JE vaccine through the 
model immunization programme in the Group A 
districts were recorded and entered into a database. 
Data on the coverage in Group B districts, where 
JE vaccine was delivered through routine EPI or 
in Group C districts with ‘free-market’ JE vaccine, 
were obtained from immunization logbooks that 
were maintained at the commune health centres.
Impact of the model programme on risk of JE
To assess the impact of the model immunization 
programme, annualized age-specific JE incidence 
rates were compared post- versus pre-vaccination 
campaign. The Wilcoxon Rank-Sum test was used 
for the analysis of rate differences of post- versus 
pre-campaign between the demonstration and 
non-demonstration districts. Computerized data-
base of vaccination records was used for validation 
of vaccination history of each confirmed JE case in 
the demonstration districts. In non-demonstration 
districts, JE vaccination history among confirmed 
JE patients were assessed by checking routine im-
munization logbooks at commune health centres 
and/or individual immunization card at home. 
Data management and data analysis
A structural data management system using Micro-
soft FoxPro® 2000 was designed for the study. All 
data were double-entered. Dual checks and error 
checks were performed on all batches of data to as-
sure validity, integrity, and confidentiality of data. 
Data were analyzed with SAS statistical software 8.1 
(SAS Institute Inc., Cary, NC, USA). 
Ethical clearance
The study was approved by the Institutional Review 
Boards (IRBs) at the National Institute of Health 
and Epidemiology (NIHE), Viet Nam, and the In-
ternational Vaccine Institute (IVI), Seoul. Confi-
dentiality of each participant was ensured, and any 
possible concern was discussed prior to the start of 
the project. 
RESULTS
Vaccination coverage 
Of 114,858 children aged 1-9 year(s) in the Group 
A districts, 109,902 (95.7%) were visited during 
the door-to-door household surveys; the remain-
ing 4,956 (4.3%) were absent and could not be 
included in the immunization programme. Of the 
109,902 children, 47,850 (43.5%) had received ≥2 
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doses of ‘free-market’ JE vaccine; thus, they were 
not eligible for participating in the model immuni-
zation programme. The remaining 62,052 (56.5%) 
children without history of JE immunization were 
enrolled in the model immunization programme. 
Assuming that, among the 4,956 children who 
were missed in the course of the household survey, 
a similar proportion has been vaccinated previously 
through the ‘free market’ as in the surveyed group, 
2,800 (4,956×56.5%) children were estimated as 
unvaccinated. 
Of the 62,052 children, 60,893 (98.1%) received 
the first dose of Green Cross JE Vaccine; 60,531 
(97.5%) returned for the second dose, and 60,165 
(96.9%) were immunized with full three doses of 
the Green Cross JE Vaccine; 1,159 children declined 
the JE vaccine. Hence, of the 114,858 children, 
4,321 were estimated as unvaccinated or received 
a single dose. The coverage with at least two doses 
of the Green Cross JE Vaccine through the model 
programme was, thus, estimated at 96.2% for the 
Group A districts. 
In the Group B districts, children aged 1-5 year(s) 
should have been immunized with locally- 
produced JE vaccine from the EPI during 1997-
2000 programme. Subsequent birth cohorts were 
immunized at 12-23 months of age during the an-
nual JE vaccination campaign. By December 2004, 
children aged 1-9 year(s) in the Group B districts 
would have been vaccinated with the locally-
produced JE vaccine. Based on the previous EPI 
documents, JE vaccine coverage in this age-group 
was 95.8% on average. 
Severe adverse events (SAE) following  
vaccination
One case with fever (39 °C) and rash was reported 
during the mass vaccination campaigns. The dis-
ease was self-limiting. The sick child was hospital-
ized and discharged one day later. 
JE incidence
From January 2004 through December 2006, 110 
acute encephalitis cases were reported; 75 (68.2%) 
were confirmed as JE via positive JEV IgM ELISA 
test in their CSFs, and 50 JE cases belonged to the 
2004 cohorts aged 1-9 year(s) whose incidence rates 
were 11.32, 2.15, and 2.79 per 100,000 in Group 
A, B and C districts respectively in 2004 (Table 1) 
and were 5.22, 7.51, and 9.75 per 100,000 respec-
tively in 2005; the rates declined significantly in 
all 3 groups in 2006. Thus, the annual incidence 
rate sharply declined for Group A and significant-
ly increased for Group B and C in 2005 (Table 1). 
The impact of the 2004 model immunization pro-
gramme on JE risk in Group A districts was, thus, 
well-demonstrated.  
In the Group A districts, JE rate peaked in 5-9 years 
age-group before implementation of the model 
programme in 2004; it drastically dropped for this 
age-group in 2005-2006 (Figure 2). In Group B dis-
tricts, JE incidence rate peaked in children younger 
than 4 years of age because children younger than 
23 months of age might not have received JE vac-
cine during annual winter campaigns. 
Impact of the model programme on risk of JE
The Wilcoxon Rank-Sum test (11) was used for 
testing the rate difference in the post- (2005-2006) 
versus pre- (2004) campaign between the dem-
onstration and non-demonstration districts. For 
each district, a rate difference was defined as post- 
campaign rate minus pre-campaign rate, and a rank 
of the rate difference was given to all 14 districts. 
Of the 9 non-demonstration districts, six reported a 
rate increase while the five demonstration districts 
all showed a rate decrease (Table 2). The Wilcoxon 
Table 1. JE incidence rate (IR) per 100,000 in 2004 cohort of 1-9 year(s) covered with different JE 
immunization programme, 2004-2006*
Group District
No. of children
[1-9 year(s)]
JE cases 2004  
(IR)
JE cases 2005  
(IR)
JE cases 2006  
(IR)
A 5 districts with  
model programme
114,858 13 
(11.32)
6 
(5.22)
1 
(0.87)
B 6 districts with  
local EPI programme
186,417 4 
(2.15)
14 
(7.51)
1 
(0.54)
C 3 districts with  
programme at user-fee 
(free-market vaccine)
71,793 2 
(2.79)
7 
(9.75)
2 
(2.78)
*In 2004, JE vaccine covered 1-9 year(s) old children only in the 6 districts of Group B; it was introduced 
into Group A during December 2004−January 2005; IR=Incidence rate (per 100,000)
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test showed statistically significant results in com-
paring the rate differences of the five demonstra-
tion districts versus the nine non-demonstration 
districts (p<0.05) as well as the six Group B districts 
(p<0.05) (Table 2). The impact of the model pro-
gramme on JE risk was, therefore, higher than of 
the national programme.
Of the seven JE cases, aged 1-9 year(s), from the 5 
demonstration districts (Group A districts) in 2005-
2006 (Table 2), five (5/4,321) had belonged to un-
immunized group, one had received 2 doses from 
the model programme in 2004 (1/60,531), a reduc-
tion of 98.5% in the vaccine group (p<0.001). An-
other case had received full 3 doses of JE vaccine 
from the ‘free market’ (1/47,850) in 2002/2003. 
No single JE case was detected among the 60,165 
children who had received full three doses of 
the vaccine from the model immunization pro-
gramme. Six JE cases aged 6-12 months (who had 
not been targeted for JE vaccination) were found 
in the Group B districts. Also, four JE cases were 
found in children between 13 and 23 months of 
age; these four children had not been immunized 
as they were born 1-11month(s) before the winter 
campaign and, thus, were not included in that re-
spective campaign. 
DISCUSSION
The model programme of JE immunization was 
well-received by parents, communities, public 
health professionals, and the Government; high 
coverage with full three doses of the vaccine was 
achieved through the current healthcare infrastruc-
ture in rural Viet Nam. The direct cost of training, 
household surveys, staff salary, and other renewable 
Figure 2. Annualized JE incidence rates by age and by programme, HaTay, Viet Nam, 2004-2006
Group A (pre-model immunization
programme) 2004
Group A (post-model immunization
programme) 2005-2006
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materials for vaccination campaign was only US$ 
0.22 per dose. The time required for each round of 
campaign was only 2-3 days. Therefore, immuniza-
tion of 1-9 year(s) old children, with three standard 
doses, was feasible and acceptable.
The difference in the trend of JE risk between the 5 
demonstration and the 9 non-demonstration dis-
tricts, especially between Group A and B districts, 
was statistically significant. The higher impact of 
the model programme compared to the national 
programme on the JE risk reduction cannot be 
explained by different vaccine coverage, which 
was 95.8% for the Group B districts and 96.2% 
for the Group A districts. The drastic decline of JE 
incidence rate in Group A districts was due to ef-
fective immunization of most susceptible children 
immediately before the epidemic year 2005; the 
rate increase in the Group B districts in 2005 was 
possibly associated with the waning immunity or 
inadequate protection of the three-paediatric dose 
regimen for older children. The use of different JE 
vaccines in the various districts was a limitation of 
the study. However, these vaccines are produced by 
different manufactures using the same technology. 
A recent study found that the effectiveness of the 
Vietnamese JE vaccine was similar to that reported 
in Thailand and Taiwan where the same vaccine 
was delivered but a total of 4 or 5 doses were admin-
istered to children through routine immunization 
programme (12). To avoid the waning immunity or 
Table 2. JE incidence rates among children aged 1-9 year(s) in post- (2005-2006) versus pre- (2004) 
vaccination period in 14 districts of HaTay province, Viet Nam
District Group 
JE cases in pre- vaccination 
period (incidence rate, 
per 100,000)
JE cases in post-vaccina-
tion period (incidence 
rate, per 100,000)
Risk  
difference
Rank*
Son Tay A 3 (19.55) 0 (0) -19.55 2
Hoai Duc A 2 (6.68) 2 (3.34) -3.34 6
Dan Phuong A 5 (25.30) 2 (5.06) -20.24 1
Thach That A 2 (8.10) 2 (4.05) -4.05 5
Phu Xuyen A 1 (3.98) 1 (1.99) -1.99 7
Ba Vi B 0 (0) 3 (4.30) 4.30 12 
Quoc Oai B 0 (0) 0 (0) 0.00 8
Chuong My B 1 (2.35) 4 (4.71) 2.35 10
Thanh Oai B 1 (3.19) 4 (6.37) 3.19 11
Ung Hoa B 2 (6.36) 1 (1.59) -4.77 4
My Duc B 0 (0) 3 (5.99) 5.99 13
Phuc Tho C 0 (0) 1 (2.03) 2.03 9
Thung Tin C 1 (3.06) 8 (12.22) 9.17 14
Ha Dong C 1 (6.94) 0 (0) -6.94 3
*Wilcoxon Rank Sum Test: p=0.0329 Group A vs Group (B+C); p=0.0358 Group A vs Group B
the inadequate protection conferred by the three-
paediatric dose regimen, we recommend a fourth 
dose at 5-9 years of age as was done routinely in Ja-
pan, Korea, and Taiwan, where the same JE vaccine 
was used, and their JE immunization programmes 
were more successful in the control of JE (13-15). It 
is important to note that inclusion of 5-9 years old 
children in the vaccination campaign has increased 
the impact of the model programme. 
In the Group B districts, JE incidence rate in the 
10-14 years age-group was similar to or higher than 
the rate in 5-9 years age-group (Figure 2). Had the 
local JE immunization programme been targeted 
also to those children who were 5-9 years of age 
during 1997-2000 as we did in the current model 
programme, the rate in the 10-14 years age-group 
in 2004-2006 would have been reduced consider-
ably. Therefore, we recommend the inclusion of 
5-9 years age-group in the catch-up JE immuniza-
tion campaign. Analysis of the situation and rec-
ommendations for modification of the national JE 
immunization programme were discussed in an-
other article. 
In this study, we had no randomly-allocated con-
trol group for comparison of JE risk. In spite of the 
fact that all 14 districts in HaTay were close neigh-
bours in the same suburb of Hanoi, the decreased 
JE rate post- versus pre-campaign in the Group A 
districts and the increased rate in the Group B dis-
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tricts could be partially due to variation of JE risk by 
year and place. In addition, there are no sufficient 
data to assess the effectiveness of the three paediat-
ric doses because only 15% of the immunized chil-
dren in the Group B districts received JE vaccine 
at 3-5 years of age. Longer follow-up and further 
study are necessary to look into these issues. Final-
ly, unlike in Group A districts where we estimated 
the vaccine coverage rate by using our field survey 
data, in Group B and C districts, we directly used 
the government data as a basis for vaccine coverage 
estimate, which may introduce some measurement 
bias. 
The seroconversion and geometric mean titre 
(GMT) of the neutralizing antibody to the local-
ly-produced JE vaccine was almost the same as, 
if not better than, the inactivated mouse brain-
derived JE vaccine produced by the Biken Insti-
tute, Japan. So far, no conclusion can be made 
that the effectiveness of the Green Cross JE 
Vaccine was different from the local JE vaccine 
which costs only US$ 0.15 per paediatric dose, 
and the vaccine production has been increasing 
steadily. If the policy can be changed to include 
5-9 years old children in the catch-up campaign 
and administer the 4th dose to those of 5-9 years 
old children who had received three paediatric 
doses through the national JE immunization pro-
gramme, the goal of JE control in Viet Nam could 
be a reality in the near future. 
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